Background: Treat-to-target (T2T) is the established management of rheumatoid arthritis (RA) patients, with recommended goals being remission/low disease activity. Patients often fail to reach these, many remaining in moderate disease activity (MDAS). This is a particular problem in the UK, with biologic and targeted synthetic DMARDs (tsDMARDs) restricted to patients with high disease activity. Identifying persistent MDAS patients with poor functional outcomes may help identify those more likely to benefit from treatment intensification. We aimed to identify predictors of disability in patients in persistent MDAS, managed in a T2T routine care setting. Methods: We retrospectively identified patients in persistent MDAS (defined as two consecutive DAS28 of between 3.2 and 5.1) from the Guy's Hospital RA Centre Database. DAS28-ESR (disease activity) and HAQ-DI (disability) scores were routinely measured at each visit. Patients were managed using T2T and were biologic-naïve at baseline (second MDAS time-point). Associations between demographic/ disease-specific factors at baseline and HAQ-DI scores at approximately 12 months, and approximate 12-month changes in HAQ-DI scores were evaluated using linear regression models. Variables with a P-value <0.1 in univariate models were subsequently included in a multivariate regression model. Results: 207 patients met our persistent MDAS definition; 81% were female, and 64% RF-positive. Mean baseline DAS28 and HAQ-DI scores were 3.98 and 1.21, respectively, indicating moderate disability. 12-month changes in HAQ-DI were minimal, with 43% of patients having a change of < 0.22 units. Baseline HAQ-DI was the dominant predictor of 12-month HAQ-DI (explaining 61% of the variance in univariate modelling). In a multivariate model, only baseline HAQ-DI retained a significant association (Table) . The ß-coefficient of 0.79 indicated that per unit increase in baseline HAQ-DI, a 0.79 unit higher end-point HAQ-DI was seen. Baseline HAQ-DI also associated with 12-month changes in HAQ-DI (multivariate model beta¼-0.21; P < 0.001) although it only explained 9% of the variance in univariate modelling. Conclusion: Patients in persistent MDAS had poor functional outcomes, many with moderate levels of disability which persisted over 12 months. The key predictor of 12-month HAQ-DI scores was the baseline HAQ-DI score. Disclosures: J.M. has shareholder/stock in Eli Lilly and Company. B.K. has received honoraria from Eli Lilly and Company, and Jansen and is a member of speakers' bureau for Eli Lilly and Company and 212 
